IgA and IgG are the two most abundant antibody classes in the human body, but they patrol very different territories. IgG dominates in the bloodstream, where it tags pathogens for destruction by immune cells and activates complement proteins that punch holes in invaders. IgA dominates at mucosal surfaces like the gut, airways, and urogenital tract, where it quietly intercepts threats before they ever reach the blood. More IgA is produced daily than all other antibody classes combined, yet IgG gets most of the attention in medicine because it is easier to measure, easier to manufacture, and better understood therapeutically.
Where Each Antibody Operates
The simplest way to think about IgA and IgG is by location. IgG is the workhorse of systemic immunity. It circulates in blood and tissue fluids, crosses the placenta to protect the developing fetus, and accounts for roughly 75% of the antibodies in serum. IgA, by contrast, is the dominant antibody at every mucosal barrier: the lining of the intestines, the respiratory tract, the mouth, and the urogenital system. It is also present in serum at meaningful concentrations, making it more than a purely mucosal player, but its defining role is at the surfaces where the body meets the outside world.1PubMed Central. IgA: Structure, Function, and Developability
This division of labor makes biological sense. Mucosal surfaces are enormous, with the gut alone covering an area comparable to a studio apartment, and they are constantly exposed to food particles, commensal bacteria, and incoming pathogens. IgA is built for that environment. IgG, meanwhile, is optimized for dealing with threats that have already breached the outer barriers and made it into the blood or deep tissues.
How They Differ in Structure
Both IgA and IgG have the classic Y-shaped antibody architecture: two arms that bind to targets and a stem (the Fc region) that communicates with immune cells. But beyond that shared blueprint, the two classes diverge in ways that matter for function.
IgG circulates mostly as a single Y-shaped molecule, a monomer. IgA in the blood is also monomeric, but the IgA secreted onto mucosal surfaces takes a different form. Two IgA molecules link together through a small joining chain, and a protective wrapper called the secretory component gets added during transport across epithelial cells. This resulting molecule, secretory IgA, is bulkier and sturdier than serum IgA. The secretory component shields the antibody from the harsh enzymes and low pH of environments like the gut lumen.2PubMed Central. The structures of secretory and dimeric immunoglobulin A The secretory component also contributes directly to immune exclusion, the process by which IgA blocks pathogens from reaching epithelial cells.3Immunity. Secretory Component: A New Role in Secretory IgA-Mediated Immune Exclusion In Vivo
IgG, by remaining a simple monomer, stays small enough to diffuse easily through tissues and cross the placenta. That structural simplicity is one reason IgG has become the backbone of therapeutic antibody development, while IgA’s complexity has kept it on the sidelines.
Subclasses and What They Do Differently
Both IgA and IgG come in subclasses, each with its own specialization. IgG has four: IgG1, IgG2, IgG3, and IgG4. They differ mainly in their hinge regions and in how well they activate complement or trigger immune cells. IgG1 and IgG3 are the strongest activators of complement and the most effective at triggering phagocytosis and cell killing. IgG2 is better suited for responses against bacterial carbohydrate antigens, and IgG4 is the least inflammatory, sometimes acting more as a blocking antibody.4PubMed Central. IgG subclasses and allotypes: from structure to effector functions Even between IgG1 and IgG3, which is “better” at killing target cells depends on the specific target, with IgG3 outperforming IgG1 in some cellular contexts and the reverse holding true in others.5PubMed Central. The Influence of Human IgG Subclass and Allotype on Complement Activation
IgA has two subclasses: IgA1 and IgA2. IgA1 has a long, heavily glycosylated hinge region, which gives it extra flexibility for binding antigens. The trade-off is that many bacteria have evolved proteases that can snip through that exposed hinge. IgA2 has a shorter hinge region that resists those bacterial enzymes, making it the tougher variant at mucosal sites where bacteria are abundant.6PubMed Central. Immunoglobulin A Antibodies: From Protection to Harmful Roles In the gut, where the microbial load is immense, IgA2 predominates. In the upper airways and serum, IgA1 is more common. This protease resistance has also been demonstrated against parasites: when the amoeba responsible for amoebic dysentery degraded both IgA subclasses, IgA2 held onto its function better than IgA1, mirroring its greater resistance to bacterial proteases.7PubMed. Degradation of human secretory IgA1 and IgA2 by Entamoeba histolytica surface-associated proteolytic activity
How Each Gets to Where It Needs to Be
IgA and IgG rely on completely different receptor systems to cross cellular barriers. IgA is transported across mucosal epithelial cells by the polymeric immunoglobulin receptor, which grabs dimeric IgA on the blood-facing side of an epithelial cell, shuttles it through the cell interior, and releases it on the mucosal surface. During this journey, part of the receptor gets clipped off and stays attached to the IgA molecule as the secretory component.
IgG uses a different receptor called FcRn, the neonatal Fc receptor. This receptor exploits the difference in pH between different sides of a cell: it binds IgG tightly in mildly acidic conditions (around pH 6.0 to 6.5) and releases it at the neutral pH (around 7.4) found in the blood.8PubMed Central. FcRn-mediated antibody transport across epithelial cells revealed by electron tomography This pH-dependent trick is what allows IgG to cross the placenta from mother to fetus and to cross the intestinal lining in newborns drinking breast milk. When both receptor systems have been studied side by side in the same cell type, they move their cargo in opposite directions: the IgA receptor sends IgA outward toward the mucosal surface, while FcRn moves IgG inward toward the blood side.9PubMed Central. Comparison of FcRn- and pIgR-mediated transport in MDCK cells by fluorescence confocal microscopy
FcRn also extends IgG’s lifespan. By rescuing IgG molecules from degradation inside cells and recycling them back into circulation, FcRn gives IgG a serum half-life of roughly three weeks. IgA, lacking this recycling mechanism, has a much shorter half-life in the blood, on the order of a few days. That difference has major implications for drug design, which we will get to.
Protecting Newborns Through Different Routes
Mothers pass protective antibodies to their babies through two complementary routes, and IgA and IgG each own one. IgG is the antibody that crosses the placenta. Maternal IgG is actively transported across the placental barrier via FcRn, so a newborn arrives with a circulating IgG repertoire that mirrors the mother’s infection history and vaccination status.10PubMed Central. A Double-Edged Sword: Breast Milk-Derived Maternal Antibodies and Infant Vaccine Responses: A Narrative Review This gives the baby systemic protection during the months before its own immune system gets up to speed.
IgA, meanwhile, dominates in breast milk. In human colostrum and mature milk, more than 80% of antibodies are IgA, with IgG making up only about 5%.11The Journal of Immunology. Advancing protective effects of maternal antibodies in neonates through animal models This IgA-heavy profile is an evolutionary adaptation specific to primates: because humans already transfer so much IgG across the placenta during pregnancy, the milk can specialize in mucosal defense instead. The secretory IgA in breast milk coats the infant’s gut lining, helping to exclude pathogens at a time when the baby’s own mucosal immune system is still immature.
IgG’s Systemic Arsenal
In the bloodstream, IgG can call on several powerful effector mechanisms. When IgG binds to a pathogen or an infected cell, its Fc region recruits natural killer cells (which destroy the target) and macrophages (which engulf it). IgG can also activate the complement cascade, a chain reaction of blood proteins that ends with direct destruction of the target cell. IgG1 monoclonal antibodies, the most common format in cancer immunotherapy, rely heavily on these mechanisms: they trigger both cell-mediated killing and complement-dependent destruction of tumor cells.12PubMed Central. The Role of Complement in the Mechanism of Action of Therapeutic Anti-Cancer mAbs
IgA works differently. Rather than activating complement or orchestrating cell killing in the blood, secretory IgA at mucosal surfaces specializes in prevention. It blocks pathogens from attaching to epithelial receptors, traps them in mucus for removal, and directly neutralizes bacterial toxins. Secretory IgA also shapes the gut microbial community, promoting the growth of beneficial bacteria and keeping potentially harmful species in check through both antigen-specific binding and broader physical interactions.13PubMed Central. Secretory IgA’s complex roles in immunity and mucosal homeostasis in the gut This is a quieter, less inflammatory mode of defense. Where IgG fights fires, IgA prevents them from starting.
Keeping the Microbiome in Check
One of IgA’s most interesting roles is its relationship with the trillions of bacteria living in the gut. In healthy people, roughly 8% of fecal bacteria are coated with secretory IgA, though this figure varies widely between individuals, from under 1% to over 25%. IgG, by contrast, is virtually absent from the healthy gut lumen: fewer than 0.05% of fecal bacteria carry IgG in healthy donors.14Journal of Allergy and Clinical Immunology. Synergistic convergence of microbiota-specific systemic IgG and secretory IgA This makes sense given the transport differences described earlier: IgA is actively pumped into the gut, while IgG has no dedicated transport system moving it to the mucosal surface.
What gets more interesting is that when researchers tested serum IgG against the same gut bacteria in vitro, the IgG targeted exclusively the species that were already coated by IgA in the gut. That overlap suggests the immune system maintains a coordinated surveillance program: IgA handles the local policing in the gut itself, and systemic IgG serves as a backup defense against the same bacteria in case they breach the mucosal barrier and enter the bloodstream.14Journal of Allergy and Clinical Immunology. Synergistic convergence of microbiota-specific systemic IgG and secretory IgA When the gut becomes inflamed, the proportion of IgG-coated bacteria rises, reflecting leakage of IgG into a compartment where it does not normally operate in significant amounts.15PubMed. DOP025 Subjects sharing bacterial amplicon sequence variants exhibit differences in their IgA and IgG coating of gut bacteria, with enrichment of IgG binding for bacteria typically found in the oral cavity
When IgA or IgG Deficiency Causes Problems
Selective IgA deficiency is the most common primary immunodeficiency in people of European descent, affecting roughly 1 in 500 individuals. Many people with IgA deficiency never notice symptoms because IgG and other compensatory mechanisms can partially cover the gap. But a substantial fraction do develop recurrent infections, particularly bacterial infections of the sinuses and respiratory tract. In one study of children with complete IgA deficiency, 88% experienced recurrent bacterial infections, and all cases of severe infection occurred in the complete deficiency group.16PubMed. Susceptibility to infections in children with selective IgA- and IgA-IgG subclass deficiency When IgA deficiency coincides with deficiencies in IgG subclasses like IgG2 and IgG4, the clinical picture worsens considerably, and in some patients this combined deficiency can be an early stage of a broader immunodeficiency syndrome.16PubMed. Susceptibility to infections in children with selective IgA- and IgA-IgG subclass deficiency
IgA deficiency also carries a practical concern that many people learn about the hard way: individuals who completely lack IgA can develop anti-IgA antibodies, and if they receive a blood transfusion containing IgA, they risk a severe allergic reaction. This is uncommon but serious enough that IgA deficiency should be flagged in medical records.
IgA Nephropathy and How Both Antibodies Contribute to Disease
IgA nephropathy is the most common form of inflammatory kidney disease worldwide, and it illustrates a case where IgA and IgG cooperate in causing harm rather than preventing it. The disease involves abnormally glycosylated IgA1 molecules that have too few galactose sugars on their hinge-region O-glycans. These malformed IgA1 molecules are recognized as foreign by IgG autoantibodies, which bind to them and form immune complexes. Those complexes then deposit in the filtering units of the kidneys and trigger inflammation.17PubMed Central. Pathogenesis of IgA Nephropathy: Current Understanding and Implications for Development of Disease-Specific Treatment
Experimental work has confirmed the pathogenic role of IgG in this disease. When researchers injected the abnormal IgA1 mixed with IgG autoantibodies from patients into immunodeficient mice, the animals developed kidney deposits containing both IgA and IgG, along with complement activation and the hallmark symptoms of blood and protein in the urine. Injecting the abnormal IgA1 alone, or IgG alone, did not cause disease.18PubMed Central. Experimental evidence of pathogenic role of IgG autoantibodies in IgA nephropathy It takes both antibodies acting together for the damage to occur. This makes IgA nephropathy a genuinely autoimmune disease in which the kidneys are bystanders caught in the crossfire between a structurally abnormal IgA1 and the IgG response against it.
Diagnostic Testing and Why IgG Gets Measured More Often
When you get a blood test to check whether you have been infected with a particular virus or responded to a vaccine, the test almost always measures IgG and sometimes IgM. IgG’s long serum half-life makes it an ideal marker of past exposure or vaccination success because it persists in the blood for months to years. IgM typically rises first during an acute infection and then falls away, so finding IgM without IgG can suggest a recent or active infection.
IgA-based testing is less common but has shown up in specific diagnostic contexts. During the COVID-19 pandemic, researchers evaluated IgA-based serology and found it was reasonably sensitive at detecting infections (pooled sensitivity around 78%) but had lower specificity than IgG-based panels, meaning more false positives.19PubMed Central. Clinical applications of detecting IgG, IgM or IgA antibody for the diagnosis of COVID-19: A meta-analysis and systematic review The combination of IgM or IgG being positive achieved the highest sensitivity in that analysis, at about 79%. In practice, IgG remains the standard for most serological testing because of its reliability and persistence.
Why IgA-Based Drugs Lag Behind IgG Therapeutics
Over twenty FDA-approved monoclonal antibody drugs are based on the IgG framework, particularly IgG1. IgA-based therapeutics, despite their potential for fighting infections at mucosal surfaces and even for cancer treatment, have not made it to the clinic. Three main obstacles explain the gap: IgA is difficult to produce and purify at scale, its glycosylation pattern is highly heterogeneous (making consistent manufacturing a headache), and its short serum half-life means it would need to be dosed far more frequently than IgG-based drugs.20PubMed Central. Fc Engineering Strategies to Advance IgA Antibodies as Therapeutic Agents
Producing full secretory IgA is even harder, since it requires assembling four different protein chains (heavy chain, light chain, joining chain, and secretory component) in the correct combination. Researchers have gotten this to work in genetically modified plants, which remains one of the more promising production platforms. Monomeric IgA expression levels in plants can approach those of IgG (around 100 milligrams per kilogram of leaf tissue), but assembling the full secretory form causes significant yield drops.21Molecular Therapy. Recombinant Secretory IgA Antibodies against SARS-CoV-2 Produce Rapid Neutralization and Protection from Pathogen Infection Until manufacturing catches up, IgG will remain the default platform for therapeutic antibodies.
Mucosal Vaccines and Getting IgA Into the Picture
Standard injectable vaccines, including the mRNA COVID-19 vaccines, are excellent at generating systemic IgG responses but generally poor at eliciting IgA at mucosal surfaces. This matters because IgG in the blood does not prevent a respiratory virus from initially infecting the cells of the nose and throat, even if it prevents the infection from becoming severe. A robust mucosal IgA response could, in theory, intercept the virus at the point of entry.
Recent mouse studies have shown a promising workaround: give the standard injectable vaccine first, then follow up with an unadjuvanted protein boost delivered through the nose. In this strategy, the initial injection primes B cells in lymph nodes. When the nasal booster arrives, memory CD4+ T cells in the lung produce chemical signals that pull those primed B cells into the airway tissue, where they switch to producing IgA. The result is a mucosal IgA response built on top of the systemic IgG response that the original injection created.22Nature. Mucosal unadjuvanted booster vaccines elicit local IgA responses by conversion of pre-existing immunity in mice This “prime and pull” approach is still in animal research, but it represents one of the more concrete paths toward vaccines that engage both arms of antibody defense.
The Evolutionary Backstory
IgG and IgA did not appear together in some early ancestor. Looking across vertebrates, the building blocks of the antibody system have been shuffled and reinvented repeatedly. Cartilaginous fish like sharks have immunoglobulins, but their repertoire looks nothing like that of mammals. The emergence of something resembling IgG, including the ability to switch between antibody classes, did not happen until amphibians appeared. Mucosal immunoglobulins have their own winding evolutionary history marked by convergent evolution, where unrelated animal lineages independently arrived at similar solutions for mucosal defense.23PubMed Central. The Janus (dual) model of immunoglobulin isotype evolution: Conservation and plasticity are the defining paradigms The fact that IgA-like mucosal antibodies evolved independently in multiple lineages underscores how critical surface-level immune defense is for survival. Protecting the gut lining from microbial invasion is not a luxury; it is an evolutionary pressure strong enough to reinvent the same solution from scratch.